199 related articles for article (PubMed ID: 30842168)
1. Early Neuropathy Related to Oxaliplatin Treatment in Advanced and Recurrent Colorectal Cancer.
Nagata T; Fukuda KI; Tamai M; Taniguchi A; Kamiya H; Kambe K; Kamada Y; Iwata G; Yamaoka N
Anticancer Res; 2019 Mar; 39(3):1347-1353. PubMed ID: 30842168
[TBL] [Abstract][Full Text] [Related]
2. Preventive Effects of Renin-angiotensin System Inhibitors on Oxaliplatin-induced Peripheral Neuropathy: A Retrospective Observational Study.
Uchida M; Kawazoe H; Takatori S; Namba H; Uozumi R; Tanaka A; Kawasaki H; Araki H
Clin Ther; 2018 Jul; 40(7):1214-1222.e1. PubMed ID: 29983264
[TBL] [Abstract][Full Text] [Related]
3. Incidence, severity, longitudinal trends and predictors of acute and chronic oxaliplatin-induced peripheral neuropathy in Taiwanese patients with colorectal cancer.
Hsu SY; Huang WS; Lee SH; Chu TP; Lin YC; Lu CH; Beaton RD; Jane SW
Eur J Cancer Care (Engl); 2019 Mar; 28(2):e12976. PubMed ID: 30536809
[TBL] [Abstract][Full Text] [Related]
4. Protective effect of the oral administration of cystine and theanine on oxaliplatin-induced peripheral neuropathy: a pilot randomized trial.
Kobayashi M; Sato R; Komura T; Ichikawa H; Hirashima T; Otake S; Akazawa N; Yazawa T; Abe T; Okada T; Kakita T; Oikawa M; Tsuchiya T
Int J Clin Oncol; 2020 Oct; 25(10):1814-1821. PubMed ID: 32594273
[TBL] [Abstract][Full Text] [Related]
5. Prevention of oxaliplatin-induced peripheral sensory neuropathy by carbamazepine in patients with advanced colorectal cancer.
Lersch C; Schmelz R; Eckel F; Erdmann J; Mayr M; Schulte-Frohlinde E; Quasthoff S; Grosskreutz J; Adelsberger H
Clin Colorectal Cancer; 2002 May; 2(1):54-8. PubMed ID: 12453338
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin-Induced Neuropathy: A Long-Term Clinical and Neurophysiologic Follow-Up Study.
Kokotis P; Schmelz M; Kostouros E; Karandreas N; Dimopoulos MA
Clin Colorectal Cancer; 2016 Sep; 15(3):e133-40. PubMed ID: 27038553
[TBL] [Abstract][Full Text] [Related]
7. Oxaliplatin-induced peripheral neuropathy risk factors and management in Tunisian population.
Zribi A; Nasr SB; Hamdi S; Ayari J; Fendri S; Balti M; Haddaoui A
Pan Afr Med J; 2020; 35():83. PubMed ID: 32537086
[TBL] [Abstract][Full Text] [Related]
8. Neurotoxicity Outcomes in a Population-based Cohort of Elderly Patients Treated With Adjuvant Oxaliplatin for Colorectal Cancer.
Raphael MJ; Fischer HD; Fung K; Austin PC; Anderson GM; Booth CM; Singh S
Clin Colorectal Cancer; 2017 Dec; 16(4):397-404.e1. PubMed ID: 28434884
[TBL] [Abstract][Full Text] [Related]
9. Oxaliplatin-induced peripheral neuropathy's effects on health-related quality of life of colorectal cancer survivors.
Tofthagen C; Donovan KA; Morgan MA; Shibata D; Yeh Y
Support Care Cancer; 2013 Dec; 21(12):3307-13. PubMed ID: 23903798
[TBL] [Abstract][Full Text] [Related]
10. Hemoglobin, Body Mass Index, and Age as Risk Factors for Paclitaxel- and Oxaliplatin-Induced Peripheral Neuropathy.
Mizrahi D; Park SB; Li T; Timmins HC; Trinh T; Au K; Battaglini E; Wyld D; Henderson RD; Grimison P; Ke H; Geelan-Small P; Marker J; Wall B; Goldstein D
JAMA Netw Open; 2021 Feb; 4(2):e2036695. PubMed ID: 33587134
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness assessment of riluzole in the prevention of oxaliplatin-induced peripheral neuropathy: RILUZOX-01: protocol of a randomised, parallel, controlled, double-blind and multicentre study by the UNICANCER-AFSOS Supportive Care intergroup.
Kerckhove N; Busserolles J; Stanbury T; Pereira B; Plence V; Bonnetain F; Krakowski I; Eschalier A; Pezet D; Balayssac D
BMJ Open; 2019 Jun; 9(6):e027770. PubMed ID: 31182448
[TBL] [Abstract][Full Text] [Related]
12. Quantitative Sensory Testing at Baseline and During Cycle 1 Oxaliplatin Infusion Detects Subclinical Peripheral Neuropathy and Predicts Clinically Overt Chronic Neuropathy in Gastrointestinal Malignancies.
Reddy SM; Vergo MT; Paice JA; Kwon N; Helenowski IB; Benson AB; Mulcahy MF; Nimeiri HS; Harden RN
Clin Colorectal Cancer; 2016 Mar; 15(1):37-46. PubMed ID: 26337211
[TBL] [Abstract][Full Text] [Related]
13. Lessons learned from the maturation of a cancer drug: oxaliplatin in colorectal cancer.
Glimelius B; Nygren P
Acta Oncol; 2019 Apr; 58(4):395-397. PubMed ID: 30882261
[No Abstract] [Full Text] [Related]
14. Goshajinkigan for prevention of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis.
Kuriyama A; Endo K
Support Care Cancer; 2018 Apr; 26(4):1051-1059. PubMed ID: 29280005
[TBL] [Abstract][Full Text] [Related]
15. Peripheral neuropathy in colorectal cancer survivors: the influence of oxaliplatin administration. Results from the population-based PROFILES registry.
Beijers AJ; Mols F; Tjan-Heijnen VC; Faber CG; van de Poll-Franse LV; Vreugdenhil G
Acta Oncol; 2015 Apr; 54(4):463-9. PubMed ID: 25417732
[TBL] [Abstract][Full Text] [Related]
16. Oxaliplatin rechallenge in metastatic colorectal cancer patients with clinically significant oxaliplatin-induced peripheral neurotoxicity.
Argyriou AA; Kalofonou F; Litsardopoulos P; Anastopoulou GG; Kalofonos HP
J Peripher Nerv Syst; 2021 Mar; 26(1):43-48. PubMed ID: 33345432
[TBL] [Abstract][Full Text] [Related]
17. Late effects of oxaliplatin-induced peripheral neuropathy (LEON)--cross-sectional cohort study of patients with colorectal cancer surviving at least 2 years.
Padman S; Lee J; Kumar R; Slee M; Hakendorf P; Richards A; Koczwara B; Kichenadasse G; Sukumaran S; Roy A; Vatandoust S; Karapetis CS
Support Care Cancer; 2015 Mar; 23(3):861-9. PubMed ID: 25223350
[TBL] [Abstract][Full Text] [Related]
18. [Prevention of oxaliplatin-induced neuropathy by carbamazepine. A pilot study].
Eckel F; Schmelz R; Adelsberger H; Erdmann J; Quasthoff S; Lersch C
Dtsch Med Wochenschr; 2002 Jan; 127(3):78-82. PubMed ID: 11797144
[TBL] [Abstract][Full Text] [Related]
19. Is quantitative sensory testing helpful in the management of oxaliplatin neuropathy? a two-year clinical study.
Delmotte JB; Beaussier H; Auzeil N; Massicot F; Laprévote O; Raymond E; Coudoré F
Cancer Treat Res Commun; 2018; 17():31-36. PubMed ID: 30343217
[TBL] [Abstract][Full Text] [Related]
20. Muscle ultrasound in the assessment of oxaliplatin-induced neurotoxicity.
Pelosi L; Han CH; McKeage MJ
Clin Neurophysiol; 2020 Jan; 131(1):343-344. PubMed ID: 31706720
[No Abstract] [Full Text] [Related]
[Next] [New Search]
